Related Image: Together we stand: bacteria organize to survive hostile zones |
(Date:12/2/2009)...swire/ -- S*BIO Pte Ltd today announced data prese... at The American Society of Hematology 51st Annual... will be presented on the clinical results from th...g its safety, tolerability and pharmacokinetic/pha...g from 100 to 600 mg. These doses were administere...
(Date:12/2/2009).../PRNewswire-Asia/ -- Simcere Pharmaceutical Group,...ding pharmaceutical company,specializing in the de...,generic and proprietary pharmaceuticals in China,...ncluded in China,s National Drug Reimbursement Lis...f Human Resources and Social,Security on November ...
(Date:12/2/2009)...swire-Asia/ -- The world is going through,extraord...y is part of many,businesses and industries. It tu...ly immune to the economic downturn, because illnes...idst of the difficult times this year, the pharmac... R&D center in Shanghai, the largest of,its ki...
(Date:12/2/2009)...wire/ -- According to the National Institute of He...sed with diabetes already have some stage of diabe...the retina caused by leaky blood vessels, is a maj...is one of the most feared diabetic complications. ...had diabetes for 10 years or more will experience ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4...t. 8 Wyeth Pharmaceuticals, a,division of Wyeth (...ts have,begun for XYNTHA(TM) Antihemophilic Factor...ant factor VIII product for both the,control and p...laxis in,patients with hemophilia A, a rare, inher... using state-of-the-art manufacturing and,purifica...
...wswire-FirstCall/ - Oncolytics Biotech Inc.,("Onco...at that it has,started patient enrolment in a Phas...n of REOLYSIN(R) in combination with paclitaxel an...eck cancers. The Principal,Investigator is Dr. Mon...CTRC) at The University of Texas Health Science Ce...
...rescriber, Software Simplifies Medicare - For Free...,announced the latest release of their PlanPrescri...o longer need to worry about whether they are,gett...ns. PlanPrescriber,the brainchild of MIT Professor... advice to help seniors quickly find their best Me...
Other Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2Goat Anti-Human EML1 (K-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
BCASMC (B350-05) from European Collection of Cell Cultures (ECACC)
BAOSMC (B354-05) from European Collection of Cell Cultures (ECACC)
Adaptor for ABI 3700 (AB-0800) from ABgene
Biology Products: